Actively Recruiting
Registry Study on "Control Nocturnal Hypertension to Reach the Target "
Led by Shanghai Institute of Hypertension · Updated on 2025-01-06
4500
Participants Needed
1
Research Sites
369 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Ambulatory blood pressure monitoring (ABPM) is a major innovation in the history of hypertension diagnosis. In clinical practice, the most well established indication for using ABPM is to identify patients who have high BP readings in the office but normal readings during usual daily activities outside of this setting or vice versa, and to identify varying 24-h BP profiles. However, in recent years, there has been increasing interest in BP values during sleep, and nocturnal BP is now recognized to be superior to daytime BP in predicting fatal and nonfatal cardiovascular events (stroke, myocardial infarction, and cardiovascular death), especially in medicated patients. The current direction in the management of hypertension is toward earlier and lower BP control for 24 hours, including the nocturnal and morning periods. Therefore, it may be of great significance to pay attention to the management of nocturnal blood pressure so as to reduce the increased cardiovascular risks. Information of nocturnal hypertensive patients defined by ABPM was prospectively registered nationwide, and then to investigate whether there was difference in cardiovascular prognosis according to the control of ambulatory nocturnal blood pressure.
CONDITIONS
Official Title
Registry Study on "Control Nocturnal Hypertension to Reach the Target "
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 50-79 years old
- Clinical diagnosis of hypertension with use of antihypertensive drugs
- Nocturnal hypertension defined as nocturnal systolic blood pressure 64 130 mmHg and/or nocturnal diastolic blood pressure 64 80 mmHg
- 24-hour ambulatory blood pressure monitoring performed with validated equipment
- Willing to provide disease history and blood biochemical test data from within 6 months
- Signed informed consent
You will not qualify if you...
- Not using antihypertensive drugs
- Hospitalized hypertension patients
- Patients who are non-compliant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
Y
Yan Li, MD,PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here